Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies how well talazoparib works in treating patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has come back after previous treatment. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To evaluate the overall response rate (ORR) (confirmed and unconfirmed, complete and partial) with talazoparib (BMN 673) in HRRD Medivation (MDVN)-positive patients. SECONDARY OBJECTIVES: I. To evaluate investigator assessed progression-free survival (IA-PFS) and overall survival (OS) associated with therapy in HRRD MDVN-positive patients. II. To evaluate ORR, IA-PFS, and OS in HRRD Foundation Medicine, Inc. (FMI)-positive patients. III. To evaluate ORR in HRRD MDVN-negative/HRRD FMI-positive patients. IV. To evaluate the frequency and severity of toxicities associated with talazoparib (BMN 673) in HRRD FMI-positive patients. TERTIARY OBJECTIVES: I. To assess if the homologous recombination deficiency (HRD) score is associated with clinical outcomes (response, PFS, OS) in HRRD FMI-positive patients treated with talazoparib (BMN 673). II. To assess if the level of PARP protein expression determined by immunohistochemistry is associated with clinical outcomes (response, PFS, OS) in HRRD FMI-positive patients treated with talazoparib (BMN 673). III. To characterize pharmacokinetic properties of talazoparib (BMN 673). OUTLINE: Patients receive talazoparib orally (PO) once daily (QD) on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 1 year, every 6 months for 2 years, and at the end of year 3. ;


Study Design


Related Conditions & MeSH terms

  • ATM Gene Mutation
  • ATR Gene Mutation
  • BARD1 Gene Mutation
  • BRCA1 Gene Mutation
  • BRCA2 Gene Mutation
  • BRIP1 Gene Mutation
  • Carcinoma
  • CHEK1 Gene Mutation
  • CHEK2 Gene Mutation
  • FANCA Gene Mutation
  • FANCC Gene Mutation
  • FANCD2 Gene Mutation
  • FANCF Gene Mutation
  • FANCM Gene Mutation
  • Lung Neoplasms
  • NBN Gene Mutation
  • PALB2 Gene Mutation
  • RAD51 Gene Mutation
  • RAD51B Gene Mutation
  • RAD54L Gene Mutation
  • Recurrent Squamous Cell Lung Carcinoma
  • RPA1 Gene Mutation
  • Stage IV Squamous Cell Lung Carcinoma AJCC v7

NCT number NCT03377556
Study type Interventional
Source Southwest Oncology Group
Contact
Status Completed
Phase Phase 2
Start date March 3, 2017
Completion date April 16, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT01907438 - Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells N/A
Active, not recruiting NCT02194387 - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members N/A
Withdrawn NCT02309632 - Pancreatic Cancer Screening of High-Risk Individuals in Arkansas N/A
Active, not recruiting NCT01009788 - ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer Phase 2
Completed NCT01251874 - Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer Phase 1
Completed NCT02197000 - A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers N/A
Recruiting NCT03428802 - Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability Phase 2
Recruiting NCT04294927 - TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention N/A
Active, not recruiting NCT03943173 - Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery Early Phase 1
Active, not recruiting NCT02953457 - Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation Phase 2
Completed NCT01975363 - Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer N/A
Completed NCT01948609 - Prospective Research of Outcomes After Salpingo-oophorectomy
Active, not recruiting NCT03552471 - Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Phase 1
Recruiting NCT02225015 - Cancer Prevention in Women With a BRCA Mutation Phase 1
Active, not recruiting NCT02321228 - Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers N/A
Recruiting NCT04030559 - Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects Phase 2
Terminated NCT01905592 - A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients Phase 3
Recruiting NCT02474264 - The Link Between BRCA Mutation and Endothelial Function N/A
Active, not recruiting NCT02286687 - Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes Phase 2
Not yet recruiting NCT06392841 - Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations Phase 2